)

Poseida Therapeutics (PSTX) investor relations material
Poseida Therapeutics Stifel 2024 Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key business highlights
Poseida Therapeutics leverages a proprietary genetic engineering toolkit for both allogeneic CAR T therapies and in vivo genetic medicines, supported by major partnerships with Roche (heme malignancies) and Astellas (solid tumors).
The company’s non-viral transposon technology and CasClover gene editor offer high-fidelity gene editing and efficient gene insertion, enabling single-step processes and lower production costs.
In-house GMP manufacturing yields over 100 doses per donor batch, reducing labor and operating costs, and supports all clinical-stage programs.
Over $400 million in partnership payments and milestones have been collected in the past three years, validating the business model and funding operations.
The company is well-capitalized into early 2026, with additional potential milestone payments anticipated.
Pipeline and clinical progress
Lead program PBCMA ALLO-1 for multiple myeloma (partnered with Roche) is in Phase 1b, showing rapid patient treatment and high response rates (91% in arm C), including in high-risk and previously treated populations.
Additional programs include PCD19, CD20 ALLO-1 (B cell malignancies), a wholly owned PBCMA CD19 ALLO-1 (for myeloma, lymphoma, autoimmune), and MUC1C (solid tumors), with several INDs planned for 2025.
Genetic medicine pipeline features non-viral gene editing for hereditary angioedema (PKLKB 101) and gene insertion for hemophilia A (P-Factor VIII101), both in preclinical stages.
Early data from the hemophilia A program show stable, long-term factor VIII production in animal models, addressing durability challenges seen in other gene therapies.
The company plans further clinical data updates in 2024 and 2025, including for MUC1C and PCD19, CD20 programs.
Technology differentiation and strategy
Poseida’s allogeneic CAR T products are based on T stem cell memory cells, engineered using non-viral transposon technology for superior safety and efficacy.
The CasClover editor enables high-fidelity, single-step gene editing and insertion in resting T cells, preserving desired cell phenotypes.
Embedded safety switches and scalable manufacturing support outpatient and community-based treatment, with no need for apheresis or bridging therapy.
The BCMA/CD19 dual-targeting approach offers comprehensive B cell depletion, with potential applications in autoimmune diseases and hematologic malignancies.
The company’s platform is positioned for rapid expansion into autoimmune indications, with INDs for new assets expected in 2025.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage